Liliia Koshlak

Liliia Koshlak

Auto-generated profile, based on publicly available information

Liliia Koshlak

Wojewódzki Szpital Zespolony w Kielcach, Poland

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

6 November 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
OAOlena Abramchuk
Olena Abramchuk
LKLiliia Koshlak
Liliia Koshlak
YMYaryna Manila
Yaryna Manila
LSLesia Slobozheniuk
Lesia Slobozheniuk
ASArtem Shchebetun
Artem Shchebetun
IZIngrida Zamoyska
Ingrida Zamoyska
Background. Image-centered social media have changed how patients observe, edit, compare, and evaluate their appearance [1, 2]. Beauty filters can erase acne, pores, pigment variation, erythema, scars, and lines while also altering facial proportions, creating a continuously available idealized version of the user’s own skin and face [3]. Dermatologists and aesthetic clinicians increasingly encounter procedure requests framed by filtered selfies, influencer content, and videoconferencing images [4, 15]. The popular expression “Snapchat dysmorphia” describes part of this phenomenon but is not a recognized diagnosis and should not be used interchangeably with body dysmorphic disorder (BDD) [1, 2, 37]. Aim. To synthesize evidence along the pathway from digital modification of skin and facial appearance to appearance anxiety and cosmetic procedure requests, and to develop an evidence-informed clinical screening framework for dermatology and aesthetic medicine. Methods. A structured narrative search of PubMed/Google Scholar was conducted through 4 October 2026 using combinations of terms related to social media, filters, selfies, photo editing, skin and facial appearance, appearance anxiety, BDD, cosmetic dermatology, cosmetic surgery, screening, and aesthetic procedures. Reference lists of relevant systematic reviews, meta-analyses, clinical reviews, and professional guidance were examined. Evidence was organized by its position in the proposed clinical pathway: digital exposure and self-editing, appearance comparison and anxiety, procedure consideration, dysmorphic symptoms, and consultation outcomes. Priority was given to systematic reviews and meta-analyses, experimental and longitudinal studies, validated screening research, and clinical guidance. Results. Systematic reviews and experiments indicate that exposure to idealized appearance content can worsen short-term body or facial satisfaction and increase appearance comparison. Active behaviors, including repeated selfie editing and filter use, show more consistent associations with cosmetic procedure acceptance than total social media time. The evidence supports a plausible but not fully established pathway from digital self-modification to self-discrepancy, appearance surveillance, anxiety, and procedure requests. Effect sizes vary, most studies involve young women, and evidence linking filter exposure to completed procedures or long-term psychiatric outcomes remains limited. BDD is substantially overrepresented in dermatology and cosmetic settings. The proposed framework combines assessment of the objective dermatologic finding, digital appearance behaviors, preoccupation and impairment, validated BDD screening, expectations, prior procedures, and mental health risk to guide treatment, extended assessment, deferral, or referral. Conclusions. Filtered skin and facial images should be treated as clinically relevant sources of comparison and procedure expectations rather than as diagnostic entities. The proposed framework translates heterogeneous evidence into a reproducible consultation process. A positive BDD screen does not establish a diagnosis, but probable BDD, an anatomically impossible target, marked functional impairment, acute psychological distress, or self-harm risk should lead to postponement of elective treatment and appropriate mental health assessment.

9 November 2026 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ABAlina Biletska
Alina Biletska
OAOlena Abramchuk
Olena Abramchuk
YFYuliia Fomenko
Yuliia Fomenko
ASArtem Shchebetun
Artem Shchebetun
LKLiliia Koshlak
Liliia Koshlak
YDYuliia Dubova
Yuliia Dubova
Background: The gut–brain axis has emerged as a key regulatory network linking intestinal microbiota with central nervous system activity. Increasing evidence suggests that gut dysbiosis contributes to the pathophysiology of depression and anxiety disorders through mechanisms involving neuroinflammation, hypothalamic–pituitary–adrenal (HPA) axis dysregulation, impaired intestinal barrier integrity, altered tryptophan metabolism, and abnormal microbial metabolite production. Aim: This review aimed to summarize the current evidence regarding the role of the gut–brain axis and psychobiotics in mental health, with particular emphasis on mechanistic pathways and recent clinical studies. Material and methods: A narrative review of the literature indexed in PubMed, Scopus, and Web of Science from 2019 to 2026 was conducted. Particular attention was given to randomized controlled trials, meta-analyses, mechanistic studies, and recent reviews on psychobiotics, gut microbiota, depression, anxiety, neuroinflammation, and precision psychiatry. Results: Current evidence indicates that selected psychobiotic strains, particularly Lactobacillus and Bifidobacterium species, may improve depressive and anxiety symptoms by modulating inflammatory cytokines, microglial activation, vagus nerve signaling, short-chain fatty acid synthesis, and serotonin precursor metabolism. Clinical studies have suggested modest but clinically relevant improvements in mood, cognitive function, stress response, and sleep quality following psychobiotic supplementation. Synbiotic therapy and Mediterranean dietary interventions may further enhance therapeutic outcomes. Conclusions: The gut–brain axis is a promising target in modern psychiatry. Although psychobiotics may constitute a valuable adjunctive strategy for treating depressive and anxiety disorders, further large-scale standardized clinical studies are necessary to establish strain-specific efficacy, optimal treatment duration, and clinically applicable biomarkers.